Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dobutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 5/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dobutamine SCHEMBL28350248 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL29929447 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| (R)-Dobutamine SCHEMBL29690160 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Levdobutamine SCHEMBL29387828 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| (R)-Dobutamine SCHEMBL21238 | 1.00 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| (R)-Dobutamine SCHEMBL31681391 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL30094854 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| (R)-Dobutamine SCHEMBL9169324 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL41609 | 0.99 | LMNA (1.00) | LMNAADRB2KDM4EMAPK1OPRK1 | |
| Dobutamine SCHEMBL10816573 | 0.99 | LMNA (0.97) | LMNAADRB2KDM4EMAPK1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18477 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-12629334-B2 | Lipid emulsions and uses thereof | RESQ PHARMA, INC. (US) | 2026-05-19 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-12545948-B2 | Identification of novel loci in asthma and methods of use thereof for the diagnosis and treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027139-A1 | TREATMENT OF SLEEP APNEA WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ALDOSTERONE ANTAGONIST | VIVUS, INC. | 2026-01-29 | — | — | US | claimed |
| US-4617393-A | CONGESITIVE HEART FAILURE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-10-14 | — | — | US | claimed |
| CN-85109229-A | Preparation method and application of dobutamine salt | — | 1986-10-01 | — | — | CN | claimed |
| EP-0187019-A2 | Improvements in or relating to dobutamine salts | ELI LILLY AND COMPANY (US) | 1986-07-09 | — | — | EP | claimed |
| US-4581225-A | CARDIOTONIC AGENTS; A CATECHOLAMINE, DOBUTAMINE | ELI LILLY AND COMPANY (US) | 1986-04-08 | — | — | US | claimed |
| EP-0160501-A2 | Sustained release intranasal formulation and method of use thereof | ELI LILLY AND COMPANY (US) | 1985-11-06 | — | — | EP | claimed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | claimed |
| US-4505910-A | Amino-pyrimidine derivatives, compositions and use | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-03-19 | — | — | US | claimed |
| EP-0130735-A1 | Amino-pyrimidine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-01-09 | — | — | EP | claimed |
| US-4425336-A | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes | KEY PHARMACEUTICALS, INC. (US) | 1984-01-10 | — | — | US | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |